| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA909: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | lorlatinib (Lorviqua®) |
| Formulation | 25mg and 100mg film coated tablets |
| Reference number | 4494 |
| Indication | Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/10/2021 |
| NICE guidance | TA909: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer |